ResMed (RMD) to Release Quarterly Earnings on Thursday

ResMed (NYSE:RMD) is set to issue its quarterly earnings data after the market closes on Thursday, April 25th. Analysts expect the company to announce earnings of $1.93 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

ResMed (NYSE:RMD) last announced its quarterly earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.15 billion. ResMed had a net margin of 19.77% and a return on equity of 23.86%. ResMed’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.66 EPS. On average, analysts expect ResMed to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ResMed Stock Down 6.0 %

NYSE:RMD opened at $173.86 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.89 and a current ratio of 3.11. The firm has a market cap of $25.57 billion, a P/E ratio of 28.74, a P/E/G ratio of 2.29 and a beta of 0.67. ResMed has a fifty-two week low of $132.24 and a fifty-two week high of $243.52. The firm has a 50-day simple moving average of $186.42 and a two-hundred day simple moving average of $170.17.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Thursday, February 8th were given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 1.10%. The ex-dividend date was Wednesday, February 7th. ResMed’s dividend payout ratio (DPR) is currently 31.74%.

Analyst Ratings Changes

Several equities analysts recently issued reports on RMD shares. Needham & Company LLC upped their price objective on ResMed from $215.00 to $224.00 and gave the company a “buy” rating in a research report on Monday, April 1st. JPMorgan Chase & Co. lifted their price target on shares of ResMed from $160.00 to $195.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Royal Bank of Canada boosted their price objective on shares of ResMed from $181.00 to $182.00 and gave the company a “sector perform” rating in a report on Thursday, January 25th. UBS Group boosted their target price on shares of ResMed from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Finally, Oppenheimer raised their price target on ResMed from $185.00 to $205.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $199.20.

Insider Activity

In other news, General Counsel Michael J. Rider sold 200 shares of ResMed stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $173.25, for a total transaction of $34,650.00. Following the transaction, the general counsel now directly owns 6,688 shares of the company’s stock, valued at approximately $1,158,696. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the sale, the general counsel now directly owns 6,688 shares in the company, valued at approximately $1,158,696. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the transaction, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. Insiders sold a total of 11,216 shares of company stock valued at $2,046,617 in the last 90 days. Company insiders own 1.21% of the company’s stock.

Hedge Funds Weigh In On ResMed

A number of hedge funds have recently made changes to their positions in the business. Ossiam lifted its holdings in ResMed by 2.4% in the 1st quarter. Ossiam now owns 1,919 shares of the medical equipment provider’s stock worth $420,000 after purchasing an additional 45 shares in the last quarter. Ascent Group LLC lifted its holdings in shares of ResMed by 2.3% in the third quarter. Ascent Group LLC now owns 1,995 shares of the medical equipment provider’s stock worth $446,000 after buying an additional 45 shares in the last quarter. SeaCrest Wealth Management LLC boosted its position in shares of ResMed by 3.6% during the fourth quarter. SeaCrest Wealth Management LLC now owns 1,400 shares of the medical equipment provider’s stock worth $291,000 after acquiring an additional 48 shares during the last quarter. Capital Impact Advisors LLC grew its stake in ResMed by 3.0% during the fourth quarter. Capital Impact Advisors LLC now owns 1,916 shares of the medical equipment provider’s stock valued at $399,000 after acquiring an additional 56 shares in the last quarter. Finally, Dearborn Partners LLC increased its holdings in ResMed by 3.8% in the 3rd quarter. Dearborn Partners LLC now owns 1,577 shares of the medical equipment provider’s stock valued at $344,000 after acquiring an additional 57 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.